Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) reached a new 52-week high during trading on Thursday following a better than expected earnings announcement. The stock traded as high as $1.37 and last traded at $1.25, with a volume of 47363 shares. The stock had previously closed at $1.03.

The company reported ($0.10) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.31) by $0.21. The firm had revenue of $1.07 million during the quarter.

Separately, ValuEngine lowered Outlook Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, January 29th.

COPYRIGHT VIOLATION NOTICE: This piece of content was first posted by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The correct version of this piece of content can be viewed at

About Outlook Therapeutics (NASDAQ:OTLK)

Outlook Therapeutics, Inc, a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases.

Read More: Lock-Up Period Expiration

Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with's FREE daily email newsletter.